SuperworthDataMeds AI MEDS
- Market cap
- $6.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.9×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $8M
- −78% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
DataMeds AI trades at 0.9× sales. Its trailing earnings are negative, so it has no PE. Revenue was $8M over the last twelve months, down 78% on a year earlier.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $44.5K | $5.7M | $12.4M | $10.9M | $7.8M+17392% | $3M−47% | $1.7M−87% | $1.6M−86% | $1.8M−77% | |
| Cost of revenue | $0 | $47.1K | $5.2M | $11.2M | $10.2M | $7.3M+15352% | $2.8M−46% | $9.5M−15% | $1.4M−86% | $1.6M−78% |
| Gross profit | $0 | −$2.6K | $521.2K | $1.2M | $692.6K | $505.8K | $231K−56% | −$7.9M | $170.2K−75% | $182.2K−64% |
| SG&A | n/a | n/a | n/a | n/a | $31.2M | $5.2M | $31M | $4.1M | $5.8M−81% | $7.2M+38% |
| −$79.8K | −$573K | −$1.7M | −$3.7M | −$31.3M+39201% | −$5.5M+860% | −$31.5M+1708% | −$25.4M+577% | −$6M−81% | −$7.3M+34% | |
| Interest expense | $3.4K | $1.3K | $137.6K | $689.2K | $1.1M+32494% | $1.2M+90354% | $1.4M+936% | $875.7K+27% | $2.1M+89% | $1.6M+32% |
| Pre-tax income | −$83.1K | −$574.3K | −$1.9M | −$4.3M | −$32.4M+38916% | −$6.7M+1062% | −$34.3M+1738% | −$27.9M+543% | −$7.7M−76% | −$18.4M+175% |
| Net income | −$83.1K | −$574.3K | −$1.9M | −$4.3M | −$32.4M+38916% | −$6.7M+1062% | −$34.3M+1738% | −$27.9M+543% | −$7.7M−76% | −$18.4M+175% |
| $0.00 | −$0.50 | −$2.00 | −$4.50 | −$31.00 | −$5.40+980% | −$23.00+1050% | −$14.50+222% | −$3.50−89% | −$7.13+32% | |
| 894.4K | 918K | 968.1K | 975.4K | 1M+16% | 1.2M+35% | 1.5M+54% | 1.9M+97% | 2.1M+102% | 2.6M+108% |
Revenue: Q1 FY24: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY24: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY24: 6 months less the 3 months printed beside them.
EPS, diluted: 4 periods, Q1 FY24 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY24 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest DataMeds AI's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MEDSDataMeds AI | $6.8M | n/m | n/a | 0.9× | −78% | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| Peer median | $52.3M | 11.8× | 12.1× | 1.4× | +6% | 8.4% |
More on DataMeds AI
Each number over time
Where it ranks
Its groups
About
- Industry
- Medical - Distribution
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .